Expanding Non-Injectable Insulin Market Fueled by Escalating Obesity and Diabetes Epidemics: Transformative Forces Shaping the Non-injectable Insulin Market Landscape in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Will the Non-injectable Insulin Industry Market Size Be by 2025?
The market for non-injectable insulin has seen a swift growth in past years. It is projected to rise from $1.92 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. Factors such as better patient obedience, tackling the fear of needles, enhanced lifestyle, simplification of administration, and reliable glucose level regulation has contributed to its growth during the historic period.

What's the Long-Term Growth Forecast for the Non-injectable Insulin Market Size Through 2029?
The market size of non-injectable insulin is predicted to experience swift expansion in the coming years, reaching a valuation of $3.17 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 10.1%. This growth during the forecast period can be credited to the ongoing focus on patient adherence, enduring solutions for needle fear, advancing improvements in life quality, incessant progress in safety, and decline in the risks of infections and injuries. Key trends anticipated during this period encompass advancements in technology, development of tech-based solutions, integration of digital health, application of nanotechnology, and the use of combination therapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/non-injectable-insulin-global-market-report

What Are the Key Growth Drivers Fueling the Non-injectable Insulin Market Expansion?
The anticipated growth in the non-injectable insulin market can be attributed to escalating occurrences of obesity and diabetes. A prime concern for health, obesity marks the excessive accumulation of body fat, typically due to more calorie consumption than expenditure. Diabetes, on the other hand, is defined by a set of metabolic disorders denoted by elevated blood sugar levels for an extended duration. Non-injectable insulin, a significant tool in fighting diabetes and obesity, has the potential to ease management by overcoming limitations of insulin therapy, serving probable weight management benefits, and giving convenient treatment choices. For example, the World Heart Federation, a non-governmental Geneva-based entity, estimated in 2022 that there would be a sharp rise in global obesity, with around 2.3 billion people in 2021, consisting of children and adults, grappling with being overweight and obesity; this number is projected to reach 2.7 billion by 2025. Additionally, the British Diabetic Association, a diabetes charity in the UK, reported in April 2023 that there are 4.3 million diabetes patients and over 2.4 million people in the UK are at substantial risk of developing type 2 diabetes. The registration numbers have swelled by 148,951 from 2021-22 as against the year earlier. Hence, the upsurge in obesity and diabetes are fuelling the expansion of the non-injectable insulin market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13888&type=smp

What Are the Key Trends Driving Non-injectable Insulin Market Growth?
Leading businesses in the non-injectable insulin market are concentrating on pioneering advancements in medication delivery technologies, like the needle-free oral insulin spray, to enhance the quality of life for those who need to manage their diabetes with multiple insulin injections. A needle-free insulin spray serves as a painless, needle-free option for blood glucose regulation, providing ease since dosages can be sprayed directly into the mouth. For example, NiedlFree Technologies, a technology company based in India, launched Ozulin, an oral insulin spray, in November 2023. This spray is designed to be more user-friendly for people with diabetes, especially for those who struggle with traditional injectable insulin methods. If approved, Ozulin could revolutionize diabetes management by offering a more convenient and painless alternative to insulin injections.

How Is the Non-injectable Insulin Market Segmented?
The non-injectable insulin market covered in this report is segmented -

1) By Type: Synthetic Insulin, Semi Synthetic Insulin
2) By Product: Pills, Sprays, Other Products
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Drug Stores

Subsegments:
1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin, Short-Acting Synthetic Insulin, Intermediate-Acting Synthetic Insulin, Long-Acting Synthetic Insulin
2) By Semi-Synthetic Insulin: Modified Insulin Analogs, Combination Insulins, Biosimilar Insulins, Insulin With Extended Release Formulations

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13888&type=smp

Which Companies Are Leading the Charge in Non-injectable Insulin Market Innovation?
Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

Which Regions Are Leading the Global Non-injectable Insulin Market in Revenue?
North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13888

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.